Previous 10 | Next 10 |
ADCT-901 targets KAAG1, a novel tumor target for ADC development ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with he...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, C...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA&...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Joseph Camardo,...
Gainers: Cellect Biotechnology (NASDAQ:APOP) +39%. NeuroOne Medical Technologies (NASDAQ:NMTC) +17%. Enveric Biosciences (NASDAQ:ENVB) +16%. Impel NeuroPharma (NASDAQ:IMPL) +12%. Progenity (NASDAQ:PROG) +10%. Losers: Forte Biosciences (NASDAQ:FBRX) -81%. Evelo Biosciences (NASDAQ:EV...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Jay Feingold, M...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ADC Therapeutics Enters Financing Agreement with HealthCare Royalty Partners” ADC Therapeutics SA (NYSE: ADCT) climbed 7% from its previous close in early mo...
ADCT sells capped royalty interest on ZYNLONTA TM and Cami for $225 million upon closing with an additional $100 million in potential near-term milestone payments Royalty of 7% terminates upon payment of 2.25x to 2.50x the purchase price Proceeds to be used for con...
ADC Therapeutics SA (ADCT) Q2 2021 Results Earnings Conference Call August 03, 2021, 08:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Christopher Martin - Co-Founder, CEO Jennifer Herron - Chief Commercial Officer & SVP Jay Feingold - Chief Medical Officer, He...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q2 2021 Earnings Call Aug 03, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...